Online Program Home
My Program

Abstract Details

Activity Number: 359 - Contributed Poster Presentations: Biopharmacutical Section
Type: Contributed
Date/Time: Tuesday, July 31, 2018 : 10:30 AM to 12:20 PM
Sponsor: Biopharmaceutical Section
Abstract #330811
Title: PFS2: Event or Censor?
Author(s): Dongmei Lan* and JIll Stankowski
Companies: ICON Plc and ICON Plc
Keywords: PFS2; Bayesian model ; MNAR

Progression on next-line therapy (PFS2) is encouraged by EMA as additional endpoint to investigate the survival benefit when clinically meaningful survival benefit cannot be properly demonstrated. PFS2 defined as time from randomization to objective disease progression on next-line therapy or death from any cause. The difficulty to collect the progression information after next-line therapy leads subjects treated as censor instead of event. This may not be random between the treatment groups. Using a Bayesian model to generate the progression time for the group who are censored prior to the event of interest and who are missing not at random, is illustrated and evaluated.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2018 program